Drug Profile
Research programme: RNA interference-based viral therapeutics - Adhera Theapeutics
Alternative Names: G 00101; MDR-03030; MDRNA Dicer substrate siRNAs for influenzaLatest Information Update: 17 Apr 2019
Price :
$50
*
At a glance
- Originator Nastech Pharmaceutical Company
- Developer Marina Biotech
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections; Metapneumovirus infections
Most Recent Events
- 22 Jul 2010 Discontinued - Preclinical for Influenza virus infections in USA (Intranasal)
- 22 Jul 2010 Discontinued - Preclinical for Metapneumovirus-infections in USA (unspecified route)
- 23 Dec 2009 No development reported - Preclinical for Metapneumovirus-infections in USA (unspecified route)